{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 52,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide outlines a clinical trial structure with six cohorts testing different combinations of Dato-DXd, pembrolizumab, and platinum-based chemotherapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/22",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.76,
        "y": 0.29
      },
      "kind": "callout",
      "text": "Primary objectives: safety and tolerability. Secondary objectives: efficacy, pharmacokinetics, and antidrug antibodies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d28fd68-e177-4d2d-a817-eda1bb2803c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.395
      },
      "kind": "list",
      "text": "Key eligibility criteria: Advanced/metastatic NSCLC, Dose escalation, Dose expansion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0549198b-f3a4-4c25-a0d7-1b32594c160a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "The first 3 to 6 patients in each cohort were enrolled to confirm acceptable safety/DLT rate; the remaining patients are considered part of dose expansion...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "708238f5-af6e-4592-ab38-3762fcb32925",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.47,
        "x": 0.29,
        "y": 0.38
      },
      "kind": "table",
      "text": "Cohort 1-6 treatment regimens including Dato-DXd, pembro, and platinum CT dosages",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "557a350e-a1ac-4e0c-b093-db45a9b61421",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "TROPION-Lung02",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76b8534f-2524-413f-9db7-1b2d951867dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase Ib investigating Dato-DXd + pembrolizumab ± PDx in 1L/2L+ mNSCLC",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2252d3e-0a87-4d4b-9dc5-e2d86c784e76",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "44844d24-f4c9-4e06-a29f-dafb6007a07e",
      "evidence": "The slide contains a table with data on treatment regimens.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 15,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 1,
      "objective": "What are the benefits of AstraZeneca's pipeline?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}